Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease

被引:65
|
作者
Rice, JE
Antic, R
Thompson, PD [1 ]
机构
[1] Royal Adelaide Hosp, Univ Dept Med, Adelaide, SA 5000, Australia
[2] Royal Adelaide Hosp, Dept Neurol, Adelaide, SA 5000, Australia
[3] Royal Adelaide Hosp, Thorac Med Unit, Adelaide, SA 5000, Australia
关键词
D O I
10.1002/mds.10072
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Symptomatic respiratory disturbance as a consequence of levodopa (L-dopa) therapy for Parkinson's disease (PD) has been described only rarely and may be underrecognized in clinical practice. We report on 2 patients with PD in whom the introduction or augmentation of L-dopa therapy was associated with the development of irregular and rapid breathing. Analysis of breathing patterns before and after L-dopa demonstrated a striking change in respiratory rate after administration of L-dopa, with the emergence of irregular tachypnea alternating with brief periods of apnea, in a pattern consistent with a central origin. In both cases, the temporal relationship of the respiratory disturbance to the administration of L-dopa suggested a peak-dose drug effect. Previous reports of L-dopa-induced respiratory dyskinesia are reviewed, and the potential mechanisms whereby L-dopa might influence the central control of respiration to produce irregular breathing patterns are discussed. (C) 2002 Movement Disorder Society.
引用
收藏
页码:524 / 527
页数:4
相关论文
共 50 条
  • [41] Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson's Disease
    Song, Tianbin
    Li, Jiping
    Mei, Shanshan
    Jia, Xiaofei
    Yang, Hongwei
    Ye, Yongquan
    Yuan, Jianmin
    Zhang, Yuqing
    Lu, Jie
    FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [42] Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
    Schaeffer, Eva
    Pilotto, Andrea
    Berg, Daniela
    CNS DRUGS, 2014, 28 (12) : 1155 - 1184
  • [43] Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease
    Fraix, V
    Pollak, P
    Van Blercom, N
    Xie, J
    Krack, P
    Koudsie, A
    Benabid, AL
    NEUROLOGY, 2001, 57 (10) : S60 - S62
  • [44] Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease
    Ivanova, S. A.
    Alifirova, V. M.
    Freidin, M. B.
    Pozhidaev, I. V.
    Fedorenko, O. Y.
    Bokhan, N. A.
    Zhukova, I. A.
    Zhukova, N. G.
    Wilffert, B.
    Loonen, A. J. M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1039 - S1040
  • [45] Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
    Eva Schaeffer
    Andrea Pilotto
    Daniela Berg
    CNS Drugs, 2014, 28 : 1155 - 1184
  • [46] Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease
    Fraix, V
    Pollak, P
    Van Blercom, N
    Xie, J
    Krack, P
    Koudsie, A
    Benabid, AL
    NEUROLOGY, 2000, 55 (12) : 1921 - 1923
  • [47] White matter hyperintensities and risk of levodopa-induced dyskinesia in Parkinson's disease
    Chung, Seok Jong
    Yoo, Han Soo
    Lee, Yang Hyun
    Jung, Jin Ho
    Baik, KyoungWon
    Ye, Byoung Seok
    Sohn, Young H.
    Lee, Phil Hyu
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2020, 7 (02): : 229 - 238
  • [48] Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease
    Kobylecki, Christopher
    Burn, David J.
    Kass-Iliyya, Lewis
    Kellett, Mark W.
    Crossman, Alan R.
    Silverdale, Monty A.
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (04) : 452 - 455
  • [49] Pathophysiology of levodopa-induced dyskinesia in Parkinson's disease: Opportunities for novel treatments
    Bezard, Erwan
    BEHAVIOURAL PHARMACOLOGY, 2006, 17 (5-6): : 535 - 535
  • [50] Risk factors for levodopa-induced dyskinesia in Serbian Parkinson's disease patients
    Markovic, V.
    Djuric, G.
    Pekmezovic, T.
    Kostic, V.
    Svetel, M.
    MOVEMENT DISORDERS, 2013, 28 : S317 - S317